Antoni Ribas (professor)

Antoni Ribas is a renowned professor and researcher in the field of medicine, specifically oncology. He is best known for his significant contributions to the development of new treatments for melanoma, a type of skin cancer.

Early Life and Education[edit | edit source]

Antoni Ribas was born and raised in Barcelona, Spain. He completed his undergraduate studies in biology at the University of Barcelona, after which he pursued his medical degree from the same institution. Ribas then moved to the United States for his postgraduate training, where he completed a residency in internal medicine at the St. Vincent's Hospital, New York. He further specialized in hematology and oncology at the University of California, Los Angeles (UCLA).

Career[edit | edit source]

Ribas is currently a professor of medicine at the David Geffen School of Medicine at UCLA. He also serves as the director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center and the director of the Parker Institute for Cancer Immunotherapy Center at UCLA.

His research primarily focuses on immunotherapy, a treatment that uses the body's immune system to fight cancer. Ribas has been instrumental in the development of several breakthrough treatments for melanoma, including pembrolizumab (Keytruda) and ipilimumab (Yervoy).

Achievements[edit | edit source]

Ribas has received numerous awards and honors for his work in oncology. He is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the European Academy of Cancer Sciences. He has published over 200 peer-reviewed articles in prestigious medical journals.